Infrastructure Capital Advisors LLC Buys Shares of 8,596 Halozyme Therapeutics, Inc. $HALO

Infrastructure Capital Advisors LLC purchased a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 8,596 shares of the biopharmaceutical company’s stock, valued at approximately $673,000.

Other hedge funds have also made changes to their positions in the company. Empowered Funds LLC bought a new position in Halozyme Therapeutics during the 1st quarter worth $755,000. Acadian Asset Management LLC acquired a new position in shares of Halozyme Therapeutics during the first quarter valued at $195,000. Hsbc Holdings PLC grew its position in shares of Halozyme Therapeutics by 117.1% during the second quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company’s stock worth $522,000 after acquiring an additional 5,448 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Halozyme Therapeutics by 6.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock worth $140,000 after acquiring an additional 174 shares during the period. Finally, Baird Financial Group Inc. increased its holdings in shares of Halozyme Therapeutics by 6.2% in the 2nd quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company’s stock worth $577,000 after acquiring an additional 650 shares during the period. Institutional investors own 97.79% of the company’s stock.

Insider Activity

In related news, Director Bernadette Connaughton sold 1,626 shares of Halozyme Therapeutics stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $102.80, for a total transaction of $167,152.80. Following the transaction, the director directly owned 40,418 shares of the company’s stock, valued at $4,154,970.40. The trade was a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the firm’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the transaction, the director owned 14,462 shares of the company’s stock, valued at approximately $1,084,650. This trade represents a 33.56% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 64,103 shares of company stock worth $5,226,496 over the last 90 days. 2.50% of the stock is currently owned by company insiders.

Halozyme Therapeutics Price Performance

HALO stock opened at $108.17 on Monday. The firm’s 50-day moving average is $83.19 and its two-hundred day moving average is $73.74. The company has a market capitalization of $12.28 billion, a price-to-earnings ratio of 32.29, a price-to-earnings-growth ratio of 0.43 and a beta of 0.85. Halozyme Therapeutics, Inc. has a 52 week low of $61.22 and a 52 week high of $108.49. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business had revenue of $481.00 million during the quarter, compared to analysts’ expectations of $402.28 million. During the same period last year, the firm posted $1.54 earnings per share. The business’s revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, analysts forecast that Halozyme Therapeutics, Inc. will post 7.77 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. HC Wainwright raised their price target on shares of Halozyme Therapeutics from $95.00 to $115.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Morgan Stanley reduced their price objective on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Wells Fargo & Company increased their price objective on Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. UBS Group restated a “buy” rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Finally, Leerink Partners upgraded Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $83.00 to $110.00 in a research report on Friday, August 7th. Nine equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $91.20.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.